Oton­o­my stag­gered by an ug­ly PhI­II fail­ure for lead pipeline drug

A lit­tle more than two years ago, San Diego-based Oton­o­my $OT­IC tried to ex­plain why it was tak­ing its failed Phase IIb drug for a dis­ease called Ménière’s dis­ease — with fre­quent episodes of ver­ti­go — in­to a piv­otal study with two Phase III tri­als.

While Otividex flunked the pri­ma­ry end­point in re­duc­ing ver­ti­go fre­quen­cy, it did just bare­ly hit a mark for re­duc­ing count­ed ver­ti­go days at month 3. So they changed up the end­points to go af­ter ver­ti­go days and went in­to Phase III.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.